Case Report

Vertebral artery dissection and cerebral infarction in a patient with recurrent ovarian cancer receiving bevacizumab

Gina M. Mantia-Smaldone a, Linda J. Bagley b, Scott E. Kasner c, Christina S. Chu a,⁎

a Division of Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
b Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
c Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA

Keywords:
Bevacizumab
Adverse events
Vertebral artery dissection
Cerebrovascular accident

Case history

The patient is a 60-year-old woman with stage IIC ovarian cancer who underwent primary optimal cytoreductive surgery, including total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy in 2010. She was then randomized to Arm I of GOG 252 and received a total of six cycles of dose dense weekly intravenous (IV) paclitaxel 80 mg/m² with IV carboplatin Area under Curve (AUC) 6.0 every 21 days and IV bevacizumab 15 mg/kg every 21 days starting with cycle 2. She completed an additional six cycles of bevacizumab maintenance but was subsequently removed from the study due to disease progression by both CA125 and computed tomographic (CT) imaging. She was then started on oral cyclophosphamide 50 mg daily with bevacizumab 10 mg/kg every 2 weeks and had a great response as indicated by serial CA125 monitoring. Of note, the patient had a history of chronic hypertension which preceded her diagnosis of ovarian cancer and was not exacerbated by her treatment with bevacizumab; her blood pressures remained well controlled. With regards to her malignancy, she has remained without evidence of disease (NED) despite stopping bevacizumab treatment.

Discussion

Bevacizumab is a humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody with reported clinical benefit in the primary (Burger et al., 2011) and secondary (Burger et al., 2007; Cannistra et al., 2007) treatments of ovarian cancer. While generally well tolerated, bevacizumab has several adverse events (AEs) which can limit its use in ovarian cancer patients (Randall and Monk, 2010). Arterial thromboembolic events (ATEs), including myocardial infarction and cerebrovascular accident (CVA), have been associated with the use in ovarian cancer patients albeit with a reported low incidence ranging 0 to 3% (Randall and Monk, 2010). ATEs have also been reported with

⁎ Corresponding author at: Perelman Center for Advanced Medicine, 3400 Civic Center Boulevard, Third Floor West Pavilion, Philadelphia, Pennsylvania 19104, USA. Fax: +1 215 349 5680.
E-mail address: cchu@uphs.upenn.edu (C.S. Chu).
bevacizumab use in patients with other primary tumors (Scappaticci et al., 2007). In a post hoc analyses of 5 randomized controlled trials including 1745 patients with metastatic colorectal, breast or non-small cell lung cancers, combination therapy with bevacizumab and chemotherapy (compared to chemotherapy alone) was associated with an increased risk of ATEs (hazard ratio (HR) 2.0, 95% confidence interval (CI) = 1.05 to 3.75, p = 0.031) as well as an increase in the absolute rate of developing an ATE (5.5 vs. 3.1 events per 100 person-years, respectively, for combination therapy vs. chemotherapy alone; HR 1.8, 95% CI = 0.94 to 3.33, p = 0.076). In this analysis, ATE development was significantly associated with prior ATEs (p < 0.001) or age ≥ 65 years (p = 0.01); of note, our patient did not have either of these risk factors.

Cerebrovascular events attributed to bevacizumab treatment are infrequently reported in the literature, likely stemming from their overall low incidence. In a single institution review, 10 patients were identified with bevacizumab-associated cerebrovascular events, including intratumoral hemorrhage (n = 7), cerebral watershed infarction (n = 1), transient ischemic attack (n = 1) and left vertebral artery occlusion (n = 1) (Seet et al., 2011). Patients were treated with bevacizumab over a median duration of 3 months (range 2–4 months) for various primary tumors, including primary brain malignancies (n = 5), non-small cell lung cancer (n = 2), renal cell carcinoma (n = 1), colorectal cancer (n = 1) and recurrent angiosarcoma (n = 1). While 4 patients experienced modest recovery, six patients died within 3 months of their cerebrovascular events, emphasizing that this type of ATE is a serious AE associated with bevacizumab.

In addition to her acute PICA CVA, our patient also had evidence for a left vertebral artery dissection, an AE not previously reported with bevacizumab. Spontaneous arterial dissection is a leading etiology of ischemic strokes in patients younger than 45 years of age and accounts for up to 2% of all ischemic strokes (Fusco and Harrigan, 2011). Vertebral arterial dissection classically presents with neck or head pain followed by posterior cerebral ischemia (Fusco and Harrigan, 2011); our patient presented with both of these findings. A key anatomic feature of vertebral artery dissections is intimal disruption, a condition which promotes intramural hematoma formation and increases the risk of thromboembolic stroke (Fusco and Harrigan, 2011). While our patient has additional risk factors for stroke including hypertension and hyperlipidemia, bevacizumab may have contributed to her vertebral artery dissection (and subsequent posterior cerebral infarction) by impairing VEGF-mediated endothelial repair; it was therefore eliminated as a treatment of her recurrent ovarian cancer.

Digital subtraction angiography (DSA) is the gold standard imaging study for vertebral artery dissection; however, MRI and CT angiography (CTA) are acceptable alternatives. DSA not only can identify common findings of dissection including eccentric, smooth or irregularly tapered stenosis and intraluminal thrombus but can also identify rare pathognomonic features such as an intimal flap or double lumen (Fusco and Harrigan, 2011). Common findings of dissection seen on MRI and CTA are a crescent-shaped intramural hematoma (Goldberg et al., 1986) and an eccentric arterial lumen with mural thickening, respectively. In our patient, suspicious findings on MRI triggered further evaluation with a CTA which confirmed the vertebral artery dissection.

Spontaneous dissections are often medically managed with anti-thrombotic therapy, including antiplatelet agents or anticoagulants. Thrombolytic agents have been utilized in the treatment of acute ischemia associated with dissection-mediated thromboembolism (Fusco and Harrigan, 2011). The role of endovascular therapy, including stents and grafts, remains controversial; treatment is often reserved for those patients with symptomatic and enlarging dissections on surveillance.
imaging (Fusco and Harrigan, 2011). In general, patients with dissections have a good prognosis, with the majority of lesions resolving within three to six months following the injury (Gonzales-Portillo et al., 2002) and 50% of patients experiencing recanalization of their occlusions (Redekop, 2008). Our patient was treated with clopidogrel alone, given an allergy to aspirin, and bevacizumab was discontinued. Three months following her dissection and CVA, she continues to show significant improvement in her neurologic status corresponding with findings on her surveillance imaging.

In summary, bevacizumab is known to increase the risk of arterial thromboembolic events (Randall and Monk, 2010) and may have contributed to the development of this patient’s vertebral artery dissection and cerebrovascular accident. Bevacizumab should be used with caution in patients older than 65 years and/or those with prior ATEs or conditions predisposing them to ATEs (Randall and Monk, 2010). Further, clinicians should also educate their patients about the risk of ATEs associated with bevacizumab, regardless of risk factors, as early recognition of ATE-related symptoms is likely to result in improved patient outcomes.

Conflict of interest statement
The authors attest that there are no conflicts of interests.

References
Burger, R.A., Brady, M.F., Bookman, M.A., Fleming, G.F., Monk, B.J., Huang, H., et al., 2011. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365 (26), 2473–2483 (Dec 29).
Burger, R.A., Sill, M.W., Monk, B.J., Greer, B.E., Sorosky, J.I., 2007. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (33), 5165–5171 (Nov 20).
Cannistra, S.A., Matulonis, U.A., Penson, R.T., Hambleton, J., Dupont, J., Mackey, H., et al., 2007. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25 (33), 5180–5186 (Nov 20).
Randall, L.M., Monk, B.J., 2010. Bevacizumab toxicities and their management in ovarian cancer. Gynecol. Oncol. 117 (3), 497–504 (Jun).
Scappaticci, F.A., Skillings, J.R., Holdren, S.N., Gerber, H.P., Miller, K., Kabbazavar, F., et al., 2007. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst. 99 (16), 1232–1239 (Aug 15).
Seet, R.C., Rabenstein, A.A., Lindell, P.E., Uhm, J.H., Wijdicks, E.F., 2011. Cerebrovascular events after bevacizumab treatment: an early and severe complication. Neurocrit. Care 15 (3), 421–427 (Dec).
Fusco, M.R., Harrigan, M.R., 2011. Cerebrovascular dissections — a review part 1: spontaneous dissections. Neurosurgery 68 (1), 242–257 (Jan; discussion 57).
Goldberg, H.J., Grosman, R.I., Gomori, J.M., Asbury, A.K., Bilaniuk, L.T., Zimmerman, R.A., 1986. Cervical internal carotid artery dissecting hemorrhage: diagnosis using MR. Radiology 158 (1), 157–161 (Jan).
Gonzales-Portillo, F., Bruno, A., Biller, J., 2002. Outcome of extracranial cervicocephalic arterial dissections: a follow-up study. Neurol. Res. 24 (4), 395–398 (Jun).
Redekop, C.J., 2008. Extracranial carotid and vertebral artery dissection: a review. Can. J. Neurol. Sci. 35 (2), 146–152 (May).